Benefits

The first study reported a 93% (15 of 16 patients) treatment response, evidenced by no residual tumour on histology, although six subjects withdrew prematurely because of local skin reactions and were not included in the final analysis.88 An ITT analysis showed that 87-5% (14 of 16 patients) had no residual tumour. All immunocompromised patients showed complete clinical response within 4 weeks of therapy and histological response at 20 weeks after initiation of therapy.89

0 0

Post a comment